Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to -$2.1 million.

  • Lifecore Biomedical, Inc. \De\'s Cash from Investing Activities rose 2270.55% to -$2.1 million in Q2 2025 from the same period last year, while for May 2025 it was -$6.4 million, marking a year-over-year increase of 6512.64%. This contributed to the annual value of -$6.4 million for FY2025, which is 6512.64% up from last year.
  • Per Lifecore Biomedical, Inc. \De\'s latest filing, its Cash from Investing Activities stood at -$2.1 million for Q2 2025, which was up 2270.55% from $1.5 million recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s Cash from Investing Activities' 5-year high stood at $65.2 million during Q1 2022, with a 5-year trough of -$17.5 million in Q2 2022.
  • For the 5-year period, Lifecore Biomedical, Inc. \De\'s Cash from Investing Activities averaged around $1.8 million, with its median value being -$3.6 million (2022).
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Cash from Investing Activities soared by 13960740.74% in 2021 and then crashed by 213628.32% in 2023.
  • Lifecore Biomedical, Inc. \De\'s Cash from Investing Activities (Quarter) stood at -$5.4 million in 2021, then rose by 29.06% to -$3.8 million in 2022, then decreased by 10.73% to -$4.3 million in 2023, then surged by 42.74% to -$2.4 million in 2024, then increased by 14.06% to -$2.1 million in 2025.
  • Its Cash from Investing Activities was -$2.1 million in Q2 2025, compared to $1.5 million in Q1 2025 and -$2.4 million in Q4 2024.